Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TNXPBullishIndustry Newsnews

High materiality7/10

Tonix gains from second GPO coverage expansion for TONMYA, 52M lives

Jun 8, 2026, 9:02 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Payer coverage expansion can lift prescription volumes and time-to-revenue, with 29% of commercial lives covered by two GPOs; immediate positive price action supports this.

AI summary

What happened, with direct paths to the underlying reporting

Tonix Pharmaceuticals announces TONMYA coverage expansion through a second GPO, boosting total U.S. commercial lives to about 52 million (29%). The FDA-approved fibromyalgia drug is now also broadly accessible via Medicaid in most states, signaling potential near-term sales momentum. The stock rose on the news as payer access accelerates adoption.

Tonix expands TONMYA coverage via a second GPO; adds ~17M lives.
Total TONMYA coverage reaches ~52M U.S. commercial lives (29%).
FDA-approved TONMYA for fibromyalgia, first new FDA fibromyalgia drug in 15+ years.
Tonix stock rose ~6% to $11.75 amid news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tonix gains from second GPO coverage expansion for TONMYA, 52M lives

Tonix Expands TONMYA Patient Access, Stock Rallies Over 5%

Tonix Pharmaceuticals Reports Positive Early Adoption of TONMYA and Solid Financials

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition